FDA And CMS Should Team Up To Prevent "Part B Gaming," Kaiser Says
This article was originally published in The Pink Sheet Daily
Differences in Medicare Part B and Part D reimbursements may influence how manufacturers approach the drug approval process, Kaiser's Barrueta maintains.
You may also be interested in...
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said
Pfizer will continue to support the insomnia product for up to six months.